Exact Sciences Comapany Presentation

A new standard in non-invasive screening EXACT SCIENCES next-generation cologuard® Specificity including no findings Specificity including non-advanced findings Cancer sensitivity Curable-stage cancer sensitivity High-grade dysplasia sensitivity Advanced precancer sensitivity BLUE-C (n=20,176) 91% 93% 94% 93% 75% 43% DeeP-C (n=9,989) 87% 90% 92% 93% 69% 42% Source: Imperiale TF et al., ACG conference abstract (2023); Imperiale TF et al., N Engl J Med (2014); curable-stage cancer includes stages I to III; for specificity definitions, please refer to next-generation Cologuard top-line results press release issued June 20, 2023 7

View entire presentation